Resistance mechanisms to mTOR inhibition in renal cancer

Resistance mechanisms to mTOR inhibition in renal cancer

<p><b>Introduction</b>: Advanced clear cell renal cell cancer (CCRCC) is incurable, but molecularly targeted treatments have improved the prognosis. One such molecular target is the mammalian target of rapamycin (mTOR) and two rapalogues (everolimus and temsirolimus) have been lice...

Bibliografske podrobnosti
Glavni avtor:	Earwaker, P
Drugi avtorji:	Macaulay, V
Format:	Thesis
Jezik:	English
Izdano:	2015

Podobne knjige/članki

The effects of mTOR inhibition in ischemic stroke
od: Schneider, AM
Izdano: (2022)

mTOR Inhibition and Tuberous Sclerosis Prevention
od: J Gordon Millichap
Izdano: (2013-09-01)

mTOR Signaling in Metabolism and Cancer
od: Shile Huang
Izdano: (2020-10-01)

mTOR Dysregulation, Insulin Resistance, and Hypertension
od: Silviu Marcel Stanciu, et al.
Izdano: (2024-08-01)

mTOR Inhibition: From Aging to Autism and Beyond
od: Matt Kaeberlein
Izdano: (2013-01-01)

Cyclopamine and Rapamycin Synergistically Inhibit mTOR Signalling in Mouse Hepatocytes, Revealing an Interaction of Hedgehog and mTor Signalling in the Liver
od: Luise Spormann, et al.
Izdano: (2020-07-01)

Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition
od: Niamh Coleman, et al.
Izdano: (2021-12-01)

RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition PONE-D-17-28641
od: Earwa, P, et al.
Izdano: (2018)

Advances in the regulatory mechanisms of mTOR in necroptosis
od: Yawen Xie, et al.
Izdano: (2023-12-01)

Influenza vaccines: mTOR inhibition surprisingly leads to protection.
od: Mcmichael, A, et al.
Izdano: (2013)

Insights into the regulation of mTOR signaling and the consequences of pharmacological inhibition
od: Thoreen, Carson Cornell
Izdano: (2009)

Reversal of phenotypes of cellular senescence by pan-mTOR inhibition
od: Cox, L, et al.
Izdano: (2016)

Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition
od: Marco Cordani, et al.
Izdano: (2016-08-01)

mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer
od: Anju Kumari, et al.
Izdano: (2023-03-01)

Baicalein induces apoptosis by inhibiting the glutamine-mTOR metabolic pathway in lung cancer
od: Jingyang Li, et al.
Izdano: (2025-02-01)

Plasticity and mTOR: Towards Restoration of Impaired Synaptic Plasticity in mTOR-Related Neurogenetic Disorders
od: Tanjala T. Gipson, et al.
Izdano: (2012-01-01)

Cancer and mTOR inhibitors in kidney transplantation recipients
od: Chih-Chin Kao, et al.
Izdano: (2018-11-01)

mTOR and cancer: many loops in one pathway
od: Efeyan, Alejo, et al.
Izdano: (2012)

Differential Reponses of Hematopoietic Stem and Progenitor Cells to mTOR Inhibition
od: Aimin Yang, et al.
Izdano: (2015-01-01)

The Bumpy Road towards mTOR Inhibition in Glioblastoma: Quo Vadis?
od: Kostas A. Papavassiliou, et al.
Izdano: (2021-12-01)

Pharmacodynamic Effect of mTOR Inhibition-based Immunosuppressive Therapy on T- and B-cell Subsets After Renal Transplantation
od: Xinyi Wei, MSc, et al.
Izdano: (2024-07-01)

mTOR Signalling, Nutrients and Disease
od: Goberdhan, D, et al.
Izdano: (2008)

The mTOR pathway in the antiphospholipid syndrome
od: Ji Lanlan, et al.
Izdano: (2023-12-01)

Overview of Research into mTOR Inhibitors
od: Beibei Mao, et al.
Izdano: (2022-08-01)

The Translational Regulation in mTOR Pathway
od: Miaomiao Yang, et al.
Izdano: (2022-06-01)

IMPAIRED REGULATORY MECHANISMS OF THE mTOR SIGNALING PATHWAY IN OSTEOARTHROSIS
od: Elena Vasilyevna Chetina, et al.
Izdano: (2012-12-01)

AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers
od: Maysa M. Abu-Khalaf, et al.
Izdano: (2023-02-01)

Targeted therapy of cancer stem cells: inhibition of mTOR in pre-clinical and clinical research
od: Boram Son, et al.
Izdano: (2024-09-01)

Implication of mTOR Signaling in NSCLC: Mechanisms and Therapeutic Perspectives
od: Antonios N. Gargalionis, et al.
Izdano: (2023-08-01)

Targeting mTOR for Anti-Aging and Anti-Cancer Therapy
od: Wencheng Fu, et al.
Izdano: (2023-04-01)

Inhibition of PIKfyve Leads to Lysosomal Disorders via Dysregulation of mTOR Signaling
od: Jianhong Xia, et al.
Izdano: (2024-05-01)

Structure of the human mTOR Complex I and its implications for rapamycin inhibition
od: Yip, Calvin K., et al.
Izdano: (2012)

Flavones provide resistance to DUX4-induced toxicity via an mTor-independent mechanism
od: Justin Cohen, et al.
Izdano: (2023-11-01)

The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling
od: Rameseder, J., et al.
Izdano: (2013)

The mTOR pathway and integrating immune regulation.
od: Cobbold, S
Izdano: (2013)

Roles of mTOR in Diabetic Kidney Disease
od: Mako Yasuda-Yamahara, et al.
Izdano: (2021-02-01)

mTOR Signaling in Metabolic Stress Adaptation
od: Cheng-Wei Wu, et al.
Izdano: (2021-05-01)

The Role of mTOR and Injury in Developing Salispheres
od: Rimah Saleem, et al.
Izdano: (2023-02-01)

mTOR Signaling in Growth Control and Disease
od: Laplante, Mathieu, et al.
Izdano: (2014)

An emerging role of mTOR in lipid biosynthesis
od: Laplante, Mathieu, et al.
Izdano: (2012)